+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

LAMEA Heparin Market By Type, By Application, By Route of Administration, By End Use, By Country, Growth Potential, COVID-19 Impact Analysis Report and Forecast, 2021 - 2027

  • ID: 5387552
  • Report
  • June 2021
  • Region: Middle East, Africa
  • 93 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • B. Braun Melsungen AG
  • Fresenius SE & Co. KGaA
  • LEO Pharma A/S
  • Pfizer, Inc.
  • Sanofi S.A.
  • Viatris, Inc.
The Latin America, Middle East and Africa Heparin Market is expected to witness market growth of 7.5% CAGR during the forecast period (2021-2027).

The increasing demand for heparin among patients suffering from the chronic blood-related disorder. It is boosting the demand for heparin and expected to have an excellent impact on the market growth. According to the Centers for Disease Control and Prevention, the increasing incidence of chronic blood-related diseases such as heart disease has killed about 365,914 people in 2017. The awareness about the benefits of heparin has been increased. The awareness about the treatment and management of heart diseases is likely to improve the prospects of the heparin market in the forecast period.

Moreover, biopharmaceutical companies are actively working to develop innovative medicines to improve the therapeutic potential of heparin. The market is also driven by the various advancements for carbohydrate synthesis and building block preparation. Furthermore, government funding with an aim to improve healthcare facilities is also increasing. The extensive research and development (R&D) activities to develop heparin with ultra-low molecular weight are also creating positive growth opportunities for the market.

The health care infrastructure is not very advanced in Sub-Saharan Africa. But, the incidences of chronic heart disease are high in this region. The WHO estimated that more than 17.7 million people died from CVDs in 2015 that represents approximately 31% of all global deaths. People who are suffering from cardiovascular disease are at risk of hypertension, diabetes, hyperlipidemia. Thus, it requires early detection and management to prevent the number of deaths occurring due to CVD. The burden of cardiomyopathies, cerebrovascular disease, and rheumatic heart disease are still very predominant in many regions of Africa. Therefore, the demand for heparin for the treatment of cardiovascular disease is increasing. It is a major factor that is expected to contribute to the growth of the market during the forecast period. Heparin is used in surgery as it reduces the risk of a blood clots in the arteries, veins, or lungs. Therefore, the demand for heparin has been increased over the past few years.

The Brazil market dominated the LAMEA Inpatient Market by Country 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $204.4 million by 2027. The Argentina market is expected to witness a CAGR of 9% during (2021 - 2027). Additionally, The UAE market is expected to witness a CAGR of 7% during (2021 - 2027).

Based on Type, the market is segmented into Low Molecular Weight Heparin, Unfractionated Heparin and Ultra-low Molecular Weight Heparin. Based on Application, the market is segmented into Atrial Fibrillation, Coronary Artery Disease, Venous Thromboembolism, Renal Impairment and Other Applications. Based on Route of Administration, the market is segmented into Subcutaneous and Intravenous. Based on End Use, the market is segmented into Outpatient and Inpatient. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.

Scope of the Study

Market Segments covered in the Report:

By
    By Country
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA
    Companies Profiled
    • Baxter International, Inc.
    • B. Braun Melsungen AG
    • Fresenius SE & Co. KGaA
    • Pfizer, Inc.
    • Sanofi S.A.
    • Teva Pharmaceuticals Industries Ltd.
    • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    • Dr. Reddy’s Laboratories Ltd.
    • LEO Pharma A/S
    • Viatris, Inc.
    Unique Offerings from the Publisher
    • Exhaustive coverage
    • Highest number of market tables and figures
    • Subscription based model available
    • Guaranteed best price
    • Assured post sales research support with 10% customization free
    Note: Product cover images may vary from those shown

    FEATURED COMPANIES

    • B. Braun Melsungen AG
    • Fresenius SE & Co. KGaA
    • LEO Pharma A/S
    • Pfizer, Inc.
    • Sanofi S.A.
    • Viatris, Inc.
    Chapter 1. Market Scope & Methodology
    1.1 Market Definition
    1.2 Objectives
    1.3 Market Scope
    1.4 Segmentation
    1.4.1 LAMEA Heparin Market, by Type
    1.4.2 LAMEA Heparin Market, by Application
    1.4.3 LAMEA Heparin Market, by Route of Administration
    1.4.4 LAMEA Heparin Market, by End Use
    1.4.5 LAMEA Heparin Market, by Country
    1.5 Methodology for the research

    Chapter 2. Market Overview
    2.1 Introduction
    2.1.1 Overview
    2.1.2 Market composition and scenario
    2.2 Key Factors Impacting the Market
    2.2.1 Market Drivers
    2.2.2 Market Restraints

    Chapter 3. LAMEA Heparin Market by Type
    3.1 LAMEA Low Molecular Weight Heparin Market by Country
    3.2 LAMEA Unfractionated Heparin Market by Country
    3.3 LAMEA Ultra-low Molecular Weight Heparin Market by Country

    Chapter 4. LAMEA Heparin Market by Application
    4.1 LAMEA Atrial Fibrillation Market by Country
    4.2 LAMEA Coronary Artery Disease Market by Country
    4.3 LAMEA Venous Thromboembolism Market by Country
    4.4 LAMEA Renal Impairment Market by Country
    4.5 LAMEA Other Applications Market by Country

    Chapter 5. LAMEA Heparin Market by Route of Administration
    5.1 LAMEA Subcutaneous Market by Region
    5.2 LAMEA Intravenous Market by Region

    Chapter 6. LAMEA Heparin Market by End Use
    6.1 LAMEA Outpatient Market by Country
    6.2 LAMEA Inpatient Market by Country

    Chapter 7. LAMEA Heparin Market by Region
    7.1 Brazil Heparin Market
    7.1.1 Brazil Heparin Market by Type
    7.1.2 Brazil Heparin Market by Application
    7.1.3 Brazil Heparin Market by Route of Administration
    7.1.4 Brazil Heparin Market by End Use
    7.2 Argentina Heparin Market
    7.2.1 Argentina Heparin Market by Type
    7.2.2 Argentina Heparin Market by Application
    7.2.3 Argentina Heparin Market by Route of Administration
    7.2.4 Argentina Heparin Market by End Use
    7.3 UAE Heparin Market
    7.3.1 UAE Heparin Market by Type
    7.3.2 UAE Heparin Market by Application
    7.3.3 UAE Unfractionated Heparin Market by Route of Administration
    7.3.4 UAE Heparin Market by End Use
    7.4 Saudi Arabia Heparin Market
    7.4.1 Saudi Arabia Heparin Market by Type
    7.4.2 Saudi Arabia Heparin Market by Application
    7.4.3 Saudi Arabia Heparin Market by Route of Administration
    7.4.4 Saudi Arabia Heparin Market by End Use
    7.5 South Africa Heparin Market
    7.5.1 South Africa Heparin Market by Type
    7.5.2 South Africa Heparin Market by Application
    7.5.3 South Africa Heparin Market by Route of Administration
    7.5.4 South Africa Heparin Market by End Use
    7.6 Nigeria Heparin Market
    7.6.1 Nigeria Heparin Market by Type
    7.6.2 Nigeria Heparin Market by Application
    7.6.3 Nigeria Heparin Market by Route of Administration
    7.6.4 Nigeria Heparin Market by End Use
    7.7 Rest of LAMEA Heparin Market
    7.7.1 Rest of LAMEA Heparin Market by Type
    7.7.2 Rest of LAMEA Heparin Market by Application
    7.7.3 Rest of LAMEA Heparin Market by Route of Administration
    7.7.4 Rest of LAMEA Heparin Market by End Use

    Chapter 8. Company Profiles
    8.1 Baxter International, Inc.
    8.1.1 Company Overview
    8.1.2 Financial Analysis
    8.1.3 Regional Analysis
    8.1.4 Research & Development Expense
    8.2 B. Braun Melsungen AG
    8.2.1 Company Overview
    8.2.2 Financial Analysis
    8.2.3 Segmental and Regional Analysis
    8.2.4 Research & Development Expenses
    8.2.5 Recent strategies and developments:
    8.2.5.1 Partnerships, Collaborations, and Agreements:
    8.3 Fresenius SE & Co. KGaA
    8.3.1 Company Overview
    8.3.2 Financial Analysis
    8.3.3 Segmental and Regional Analysis
    8.3.4 Research & Development Expenses
    8.3.1 Recent strategies and developments:
    8.3.1.1 Partnerships, Collaborations, and Agreements:
    8.3.1.2 Acquisition and Mergers:
    8.3.1.3 Product Launches and Product Expansions:
    8.4 Pfizer, Inc.
    8.4.1 Company Overview
    8.4.2 Financial Analysis
    8.4.3 Regional Analysis
    8.4.4 Research & Development Expense
    8.5 Sanofi S.A.
    8.5.1 Company Overview
    8.5.2 Financial Analysis
    8.5.3 Segmental and Regional Analysis
    8.5.4 Research & Development Expense
    8.6 Teva Pharmaceutical Industries Ltd.
    8.6.1 Company Overview
    8.6.2 Financial Analysis
    8.6.3 Regional Analysis
    8.6.4 Research & Development Expenses
    8.7 Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    8.7.1 Company Overview
    8.8 Dr. Reddy’s Laboratories Ltd.
    8.8.1 Company Overview
    8.8.2 Financial Analysis
    8.8.3 Segmental and Regional Analysis
    8.8.4 Research & Development Expense
    8.9 LEO Pharma A/S
    8.9.1 Company Overview
    8.9.2 Financial Analysis
    8.9.3 Regional Analysis
    8.9.4 Research & Development Expense
    8.10. Viatris, Inc.
    8.10.1 Company Overview
    8.10.2 Financial Analysis
    8.10.3 Segmental and Regional Analysis
    8.10.4 Research & Development Expense
    Note: Product cover images may vary from those shown
    • Baxter International, Inc.
    • B. Braun Melsungen AG
    • Fresenius SE & Co. KGaA
    • Pfizer, Inc.
    • Sanofi S.A.
    • Teva Pharmaceuticals Industries Ltd.
    • Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
    • Dr. Reddy’s Laboratories Ltd.
    • LEO Pharma A/S
    • Viatris, Inc.
    Note: Product cover images may vary from those shown

    Loading
    LOADING...

    Adroll
    adroll